All In Biotech

Free tool

Drugs in development

Investigational drugs and biologics in industry-sponsored Phase 2 and Phase 3 trials that are active or finished in the last two years, and that FDA has not approved. Built from 10,322 ClinicalTrials.gov records, with code names and generic names merged. For approved drugs, use Drug Search.

Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations

Drugs in development

3,685

Not FDA-approved

In Phase 3

1,424

Highest phase reached

Matching your filters

38

Reset

38 drugs in development

Names, sponsors and conditions come from the trial records. Click a drug for its trials.

  • CadonilimabAK104Phase 331 trials

    Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma

  • Savolitinibhmpl-504, AZD6094Phase 311 trials

    AstraZeneca · Carcinoma, Non-small Cell Lung Cancer, Non-Small Cell Lung Cancer

  • ZanzalintinibXL092Phase 311 trials

    Exelixis · Colorectal Cancer, Renal Cell Carcinoma, Head and Neck Squamous Cell Carcinoma

  • Intismeran autogeneV940, mRNA-4157Phase 310 trials

    Merck & Co. · Non-small Cell Lung Cancer, Melanoma, Bladder Cancer

  • FavezelimabMK-4280, MK-4820APhase 39 trials

    Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors

  • AbexinostatPCI-24781Phase 35 trials

    Xynomic Pharmaceuticals, Inc. · Lymphoma, Follicular, Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma

  • ONC-392Gotistobart, BNT316Phase 35 trials

    OncoC4, Inc. · Non Small Cell Lung Cancer, Ovarian Cancer, Advanced Solid Tumor

  • rHuPH20Phase 35 trials

    Bristol Myers Squibb · Melanoma, Relapsing-remitting Multiple Sclerosis, Clear Cell Renal Cell Carcinoma

  • AL8326Phase 34 trials

    Advenchen Pharmaceuticals, LLC. · Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms

  • GimistotugBGB-A445Phase 34 trials

    BeOne Medicines (BeiGene) · Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma

  • CasdatifanAB521Phase 33 trials

    Arcus Biosciences, Inc. · Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Advanced Renal Cell Carcinoma (RCC)

  • MK-4830Phase 210 trials

    Merck & Co. · Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Esophageal Squamous Cell Carcinoma

  • RO7247669Tobemstomig, RG6139Phase 26 trials

    Roche (Genentech) · Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer

  • VibostolimabMK-7684Phase 26 trials

    Merck & Co. · Melanoma, Carcinoma, Non-Small-Cell Lung, Metastatic Urothelial Carcinoma

  • EnvafolimabPhase 24 trials

    3D Medicines (Sichuan) Co., Ltd. · Biliary Tract Neoplasms, Solid Tumor, Solid Tumors

  • IL-2MDNA11, Interleukin-2 -albuminPhase 24 trials

    Grit Biotechnology · Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma

  • PD-L1 t-haNKPhase 23 trials

    ImmunityBio, Inc. · Pancreatic Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer

  • REGN10597PD-1-IL2Ra-IL2 immunotherapyPhase 23 trials

    Regeneron · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

  • REGN5678NezastomigPhase 23 trials

    Regeneron · Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)

  • ST-1898Phase 23 trials

    Beijing Scitech-Mq Pharmaceuticals Limited · Advanced Renal Cell Carcinoma, Differentiated Thyroid Carcinoma, Unresectable or Metastatic Melanoma

  • Carboplatin AUC-5Phase 22 trials

    Inhibrx Biosciences, Inc · Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer

  • GI-102Phase 22 trials

    GI Innovation, Inc. · Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS)

  • ImzokitugBMS-986340Phase 22 trials

    Bristol Myers Squibb · Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC), Cervical Cancer

  • REGN4336Phase 22 trials

    Regeneron · Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)

  • WGI-0301Phase 22 trials

    Zhejiang Haichang Biotech Co., Ltd. · Advanced Hepatocellular Carcinoma (HCC), Hepato Cellular Carcinoma (HCC), Renal Cell Cancer

  • AB-2100Integrated Circuit T cellsPhase 21 trial

    Arsenal Biosciences, Inc. · Advanced/Metastatic Clear Cell Renal Cell Carcinoma, Recurrence

  • AZD6750Phase 21 trial

    AstraZeneca · Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin)

  • EB-701CA9-NKPhase 21 trial

    Beijing Biotech · Advanced or Metastatic Clear Cell Renal Cell Carcinoma

  • GI-101Phase 21 trial

    GI Innovation, Inc. · Advanced Solid Tumor, Metastatic Solid Tumor, Cervical Cancer

  • GI-101APhase 21 trial

    GI Innovation, Inc. · Advanced Solid Tumor, Metastatic Solid Tumor, Cervical Cancer

  • GI-108Phase 21 trial

    GI Innovation, Inc. · Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancer (NSCLC)

  • GM103Phase 21 trial

    GeneMedicine Co., Ltd. · Head and Neck Cancer, Malignant Melanoma, Colorectal Cancer

  • HS-10516Phase 21 trial

    Jiangsu Hansoh Pharmaceutical Co., Ltd. · Advanced Clear Cell Renal Cell Carcinoma

  • IBR854Phase 21 trial

    Imbioray (Hangzhou) Biomedicine Co., Ltd. · Renal Cell Carcinoma (RCC)

  • NDI-101150Phase 21 trial

    Nimbus Saturn, Inc. · Solid Tumor, Renal Cell Carcinoma (Kidney Cancer), Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

  • REGN15505Phase 21 trial

    Regeneron · Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)

  • ST-067Phase 21 trial

    Simcha IL-18, Inc. · Cancer, Solid Tumor, Melanoma

  • VMD-102Single agentPhase 21 trial

    VM Discovery, Inc. · Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma, Renal Cell Carcinoma (RCC)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.